查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1965780

左levofloxacin市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、通路、地區和競爭格局分類，2021-2031年

Levofloxacin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Application, By Distribution Channel, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球levofloxacin市場預計將從 2025 年的 17.6 億美元成長到 2031 年的 24.8 億美元，複合年成長率為 5.88%。

levofloxacin是一種頻譜Fluoroquinolones抗生素，透過抑制細菌DNA促旋酶和拓樸異構酶IV，成為治療社區型肺炎、急性腎盂腎炎和複雜性皮膚感染疾病等嚴重的主要藥物。推動市場成長的主要動力是感染疾病積極抗菌治療的細菌性呼吸道和尿道感染的增加。此外，人口老化也是一個重要的促進因素，因為老年人更容易出現需要住院治療和靜脈注射抗生素的急性細菌併發症。

市場概覽
預測期 2027-2031
市場規模：2025年 17.6億美元
市場規模：2031年 24.8億美元
複合年成長率：2026-2031年 5.88%
成長最快的細分市場 醫院藥房
最大的市場 北美洲

儘管市場前景廣闊，但由於持續存在的供應鏈脆弱性和生產不穩定，仍面臨許多挑戰。學名藥生產商之間的整合減少了生產冗餘，加劇了基本無菌注射劑的短缺。根據美國醫療保健系統藥劑師協會 (ASHP) 發布的《2024 年報告》，美國醫療保健系統在第一季經歷了創紀錄的 323 種藥品短缺，尤其影響了levofloxacin等關鍵藥物的穩定供應。這些供不應求中斷威脅市場穩定，迫使醫療機構限制庫存發行並轉向替代治療方法。

市場促進因素

呼吸道感染疾病和肺炎發生率的不斷上升是全球levofloxacin市場的主要驅動力。這凸顯了該藥物作為「治療呼吸道感染的Fluoroquinolones抗生素」的有效性。當標準治療無效或懷疑有非典型細菌感染時，左氧氟沙星被廣泛用於治療社區型肺炎。流行病學趨勢的變化進一步強化了人們對左氧氟沙星的依賴。例如，美國疾病管制與預防中心（CDC）在2024年10月報告稱，從春末到10月，美國所有年齡層的肺炎黴漿菌檢測陽性率從0.7%上升至3.3%。這種成長直接增加了臨床上對左levofloxacin的需求，以確保門診和住院患者獲得有效的患者照護。

同時，左氧氟沙星在治療多重抗藥性結核病（MDR-TB）的關鍵角色正顯著影響市場格局。作為二線藥物，levofloxacin對於堅持建議的短期治療方法以對抗抗藥性菌株至關重要。日益嚴重的抗藥性問題凸顯了左氧氟沙星的必要性。世界衛生組織（WHO）於10月發布的《2024年世界結核病報告》估計，到2023年，全球將有40萬人患有多重抗藥性結核病或利福平抗藥性結核病。為了應對這一日益嚴峻的威脅，需要持續供應強效Fluoroquinolones藥物來控制疫情。此外，健康指標與評估研究所（IHME）於2024年9月發布的一項研究預測，到2050年，與抗生素抗藥性相關的死亡人數可能達到每年約200萬，凸顯了左氧氟沙星在現代醫學中不可或缺的地位。

市場挑戰

持續存在的供應鏈脆弱性和生產不規範是全球levofloxacin市場發展的主要障礙。這些物流薄弱環節常常導致無菌注射嚴重短缺，而這些注射劑對於醫院治療嚴重的感染疾病和尿道感染至關重要。非專利生產設施的整合降低了生產冗餘度，這意味著即使是輕微的品質問題或原料延遲也可能導致大範圍的庫存短缺。因此，醫療機構面臨營運上的不確定性，迫使他們限制劑量或將患者轉用其他類別的抗生素。這種可靠性的缺失抑制了levofloxacin的潛在消費量，並有效地阻礙了市場成長，儘管人口老化導致臨床需求不斷增加。

近期行業統計數據凸顯了這些供應中斷的廣泛影響。根據歐洲醫院藥劑師協會 (EAHP) 於 2025 年 11 月發布的《藥品短缺調查》，抗生素是最常出現短缺的藥物類別，63% 的醫院藥劑師報告全年都面臨嚴重的短缺問題。這種反覆出現的供不應求正在削弱處方醫生的信心，迫使採購部門增加藥品庫存，並限制左levofloxacin產品的全球收入成長潛力。

市場趨勢

將levofloxacin融入生物活性傷口敷料的技術正作為創新趨勢備受關注，尤其是在治療糖尿病足潰瘍等慢性疾病方面。研發公司使用靜電紡絲技術製造了一種先進的奈米纖維支架，能夠實現抗菌藥物的持續釋放。這解決了傳統局部治療藥物代謝迅速、組織滲透性差，導致療效持續不足的問題。這項技術旨在透過確保可控的治療環境，降低複雜傷口感染的風險，從而加速患者復原。值得注意的是，貝爾法斯特女王大學於2025年10月宣布，一種新開發的含levofloxacin的靜電紡絲纖維達到了理想的400奈米直徑。這項關鍵參數最佳化了表面積，確保藥物能有效率地輸送到傷口床。

同時，眼科領域市場呈現顯著成長，一系列特定配方溶液核准並上市。這一趨勢的驅動力在於市場對穩定有效的細菌性結膜炎及其他眼部感染疾病治療方法的需求，並且關注點正從傳統學名藥轉向監管更為嚴格的產品。製藥公司正積極尋求這些改良配方的監管核准，以鞏固其在高成長區域市場的地位。例如，路透社於2025年12月報道，聯合實驗室國際控股有限公司的子公司已獲得中國國家藥品監督管理局核准，上市濃度為0.488%的左levofloxacin眼藥水。這進一步鞏固了該公司在眼科抗感染劑市場的地位。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球左levofloxacin市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 用途（肺炎、皮膚感染疾病、腎臟感染疾病、膀胱感染疾病等）
    • 分銷通路（醫院藥局、零售藥局、網路藥局）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美左levofloxacin市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲左levofloxacin市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區左levofloxacin市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：levofloxacin在中東和非洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：左levofloxacin在南美洲的市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球左levofloxacin市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Zydus Lifesciences Ltd.
  • Alna Biotech Private Limited
  • Cipla Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Zhejiang Jingxin Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • ANI Pharmaceuticals, Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19128

The Global Levofloxacin Market is projected to expand from USD 1.76 Billion in 2025 to USD 2.48 Billion by 2031, reflecting a compound annual growth rate of 5.88%. Levofloxacin, a broad-spectrum fluoroquinolone, operates by obstructing bacterial DNA gyrase and topoisomerase IV, making it a staple treatment for serious ailments like community-acquired pneumonia, acute pyelonephritis, and complex skin infections. Market growth is largely underpinned by the rising prevalence of bacterial respiratory and urinary tract infections that demand strong antimicrobial interventions. Additionally, the growing elderly population serves as a significant driver, as older adults are more prone to acute bacterial complications that necessitate hospitalization and intravenous antibiotic administration.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.76 Billion
Market Size 2031USD 2.48 Billion
CAGR 2026-20315.88%
Fastest Growing SegmentHospital Pharmacies
Largest MarketNorth America

Despite these growth prospects, the market faces substantial hurdles due to enduring supply chain weaknesses and inconsistencies in manufacturing. The consolidation of generic drug makers has diminished production redundancy, worsening availability problems for essential sterile injectables. As reported by the American Society of Health-System Pharmacists in 2024, the US healthcare system experienced a record high of 323 active drug shortages in the first quarter, a deficit that specifically impacted the steady supply of vital drugs like Levofloxacin. These interruptions threaten market stability and compel healthcare facilities to ration their stocks or switch to different therapeutic options.

Market Driver

The increasing frequency of respiratory tract infections and pneumonia acts as a major engine for the Global Levofloxacin Market, highlighted by the drug's effectiveness as a "respiratory fluoroquinolone." It is widely utilized for community-acquired pneumonia when standard treatments are ineffective or atypical bacteria are suspected. This reliance is reinforced by shifting epidemiological trends; for instance, the Centers for Disease Control and Prevention reported in October 2024 that test positivity for Mycoplasma pneumoniae rose from 0.7% to 3.3% across all US age groups between late spring and October. Such increases directly boost the clinical necessity for Levofloxacin to ensure effective patient care in both outpatient and hospital environments.

Simultaneously, the market is heavily shaped by the antibiotic's vital function in treating multi-drug resistant tuberculosis (MDR-TB). Classified as a primary second-line medication, Levofloxacin is crucial for compliance with recommended shorter treatment regimens for resistant strains. The necessity of this role is emphasized by the growing burden of resistance; the World Health Organization's 'Global Tuberculosis Report 2024', released in October, estimated that 400,000 individuals worldwide developed multidrug-resistant or rifampicin-resistant tuberculosis in 2023. This rising threat demands the continued availability of potent fluoroquinolones for outbreak control. Furthermore, a September 2024 study by the Institute for Health Metrics and Evaluation projects that deaths linked to antimicrobial resistance could reach nearly 2 million annually by 2050, confirming the drug's essential status in modern medicine.

Market Challenge

Ongoing supply chain fragilities and manufacturing irregularities pose a major obstacle to the Global Levofloxacin Market's development. These logistical weaknesses often lead to severe shortages of sterile injectable forms, which are critical for managing serious respiratory and urinary tract infections in hospitals. The merging of generic manufacturing facilities has lowered production redundancy, meaning even minor quality issues or raw material delays can trigger widespread inventory gaps. As a result, healthcare providers encounter operational unpredictability and are forced to ration doses or move patients to different antibiotic classes. This unreliability curbs the potential consumption of Levofloxacin, effectively hindering market growth despite increasing clinical needs from an aging demographic.

The widespread impact of these disruptions is highlighted by recent industry statistics. The European Association of Hospital Pharmacists (EAHP) revealed in their November 2025 Shortages Survey that antimicrobial agents were the drug class most often in short supply, with 63% of hospital pharmacists noting critical unavailability throughout the year. Such recurrent supply voids erode prescriber trust and compel procurement teams to broaden their therapeutic inventories, thereby restricting the global revenue growth potential for Levofloxacin products.

Market Trends

The incorporation of Levofloxacin into bioactive wound dressings is gaining traction as a transformative trend, especially for treating chronic issues like diabetic foot ulcers. Innovators are utilizing electrospinning technology to develop advanced nanofiber scaffolds that permit sustained antibiotic release, addressing the shortcomings of traditional topical treatments that often fail due to rapid clearance and weak tissue penetration. This advancement aims to improve patient recovery by ensuring a controlled therapeutic setting that reduces infection risks in complex wounds. Notably, Queen's University Belfast reported in October 2025 that their newly developed Levofloxacin-loaded electrospun fibers achieved an ideal diameter of 400 nm, a key specification for optimizing surface area and ensuring efficient drug delivery to the wound bed.

At the same time, the market is experiencing significant growth in the ophthalmic sector, marked by the ongoing approval and launch of specific solution formulations. This trend is fueled by the demand for stable, effective treatments for bacterial conjunctivitis and other eye infections, shifting focus from older generic options to more rigorously regulated products. Pharmaceutical firms are aggressively seeking regulatory approvals for these refined solutions to bolster their presence in high-potential regional markets. For example, Reuters reported in December 2025 that a subsidiary of United Laboratories International Holdings Ltd. secured marketing approval from China's National Medical Products Administration for Levofloxacin Eye Drops with a precise 0.488% concentration, strengthening the company's standing in the ophthalmic anti-infective landscape.

Key Market Players

  • Zydus Lifesciences Ltd.
  • Alna Biotech Private Limited
  • Cipla Ltd
  • Glenmark Pharmaceuticals Ltd.
  • Lupin Limited
  • Zhejiang Jingxin Pharmaceutical Co., Ltd.
  • Pfizer Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • ANI Pharmaceuticals, Inc.

Report Scope

In this report, the Global Levofloxacin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Levofloxacin Market, By Application

  • Pneumonia
  • Skin Infection
  • Kidney Infection
  • Bladder Infection
  • Other

Levofloxacin Market, By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Levofloxacin Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Levofloxacin Market.

Available Customizations:

Global Levofloxacin Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Levofloxacin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Pneumonia, Skin Infection, Kidney Infection, Bladder Infection, Other)
    • 5.2.2. By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Levofloxacin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Distribution Channel
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Levofloxacin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
        • 6.3.1.2.2. By Distribution Channel
    • 6.3.2. Canada Levofloxacin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
        • 6.3.2.2.2. By Distribution Channel
    • 6.3.3. Mexico Levofloxacin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application
        • 6.3.3.2.2. By Distribution Channel

7. Europe Levofloxacin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Distribution Channel
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Levofloxacin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
        • 7.3.1.2.2. By Distribution Channel
    • 7.3.2. France Levofloxacin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
        • 7.3.2.2.2. By Distribution Channel
    • 7.3.3. United Kingdom Levofloxacin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
        • 7.3.3.2.2. By Distribution Channel
    • 7.3.4. Italy Levofloxacin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
        • 7.3.4.2.2. By Distribution Channel
    • 7.3.5. Spain Levofloxacin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application
        • 7.3.5.2.2. By Distribution Channel

8. Asia Pacific Levofloxacin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Distribution Channel
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Levofloxacin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
        • 8.3.1.2.2. By Distribution Channel
    • 8.3.2. India Levofloxacin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
        • 8.3.2.2.2. By Distribution Channel
    • 8.3.3. Japan Levofloxacin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
        • 8.3.3.2.2. By Distribution Channel
    • 8.3.4. South Korea Levofloxacin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
        • 8.3.4.2.2. By Distribution Channel
    • 8.3.5. Australia Levofloxacin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application
        • 8.3.5.2.2. By Distribution Channel

9. Middle East & Africa Levofloxacin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Distribution Channel
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Levofloxacin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
        • 9.3.1.2.2. By Distribution Channel
    • 9.3.2. UAE Levofloxacin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
        • 9.3.2.2.2. By Distribution Channel
    • 9.3.3. South Africa Levofloxacin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application
        • 9.3.3.2.2. By Distribution Channel

10. South America Levofloxacin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Distribution Channel
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Levofloxacin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
        • 10.3.1.2.2. By Distribution Channel
    • 10.3.2. Colombia Levofloxacin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
        • 10.3.2.2.2. By Distribution Channel
    • 10.3.3. Argentina Levofloxacin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application
        • 10.3.3.2.2. By Distribution Channel

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Levofloxacin Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Zydus Lifesciences Ltd.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Alna Biotech Private Limited
  • 15.3. Cipla Ltd
  • 15.4. Glenmark Pharmaceuticals Ltd.
  • 15.5. Lupin Limited
  • 15.6. Zhejiang Jingxin Pharmaceutical Co., Ltd.
  • 15.7. Pfizer Inc.
  • 15.8. Dr. Reddy's Laboratories Ltd.
  • 15.9. Teva Pharmaceutical Industries Ltd.
  • 15.10. ANI Pharmaceuticals, Inc.

16. Strategic Recommendations

17. About Us & Disclaimer